Actively Recruiting
Pyrophosphate and Arterial Calcification in Chronic Kidney Disease
Led by Centre Hospitalier Universitaire de Nice · Updated on 2024-10-15
242
Participants Needed
1
Research Sites
313 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Arterial calcifications start at early stages of chronic kidney disease (CKD) and are associated to cardiovascular mortality. Pyrophosphate (PPi) is an endogenous compound, which stops the mineralization process in bones and is expected to act at ectopic sites. In uremic rats, low PPi plasma levels are associated with high calcium content in the aorta and peritoneal administration of PPi blocks this process. People on maintenance dialysis or kidney transplant recipients have low plasma levels of PPi and show high scores of arterial calcification. The purpose is to determine the role of low PPi in the development of arterial calcifications in patients with CKD stage 3 or 4. To that aim, 252 patients with eGFR between 59 et 20 ml/min/1,73 m2 will be recruited and will be examined at baseline and three years later.
CONDITIONS
Official Title
Pyrophosphate and Arterial Calcification in Chronic Kidney Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- eGFR between 59 and 20 ml/min/1,73 m2 measured twice over a three month interval
You will not qualify if you...
- History of kidney transplantation
- Presence of acute inflammatory disease or active cancer
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU de Nice
Nice, Alpes Maritimes, France, 06001
Actively Recruiting
Research Team
F
Favre Guillaume, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here